SCHEMBL8901370

SCHEMBL8901370

CC(=O)c1ccc2nc(N[RaH])ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.45
MAPT P10636 6/20 0.44
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
PLK1 P53350 1/20 0.41
MTOR P42345 1/20 0.40
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
TNNI3 P19429 1/20 0.39
TNNT2 P45379 1/20 0.39
TNNC1 P63316 1/20 0.39
RUNX1 Q01196 1/20 0.39
CBFB Q13951 1/20 0.39
PDE4B Q07343 1/20 0.39
SLC2A1 P11166 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8900244 0.81 NPC1 (0.33) MAPTNPC1RAB9APLK1MTOR
SCHEMBL29371543 0.78 CYP2A6 (0.49) CYP2A6MAPTALDH1A1HPGDNPC1
SCHEMBL3717520 0.78 CYP2A6 (0.49) CYP2A6MAPTALDH1A1HPGDNPC1
SCHEMBL8899884 0.76 MTOR (0.34) NPC1RAB9AKMT2AMEN1PLK1
SCHEMBL31201668 0.76 NPC1 (0.55) CYP2A6MAPTALDH1A1HPGDNPC1
SCHEMBL5095477 0.76 NPC1 (0.55) CYP2A6MAPTALDH1A1HPGDNPC1
SCHEMBL8900141 0.76 KDM4E (0.44) MAPTNPC1RAB9AKMT2AMEN1
SCHEMBL8901234 0.75 CYP3A4 (0.50) MAPTHPGDNPC1RAB9AKMT2A
SCHEMBL8902299 0.75 MAPT (0.47) MAPTALDH1A1NPC1RAB9AKMT2A
SCHEMBL4407433 0.75 NCF1 (0.48) CYP2A6MAPTALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B CYP2A6 2159/4885MAPT 905/4885ALDH1A1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.